Exposure of human pancreatic islets to a mixture of cytokines induces expression of inducible nitric oxide synthase (iNOS), impairs beta-cell function and induces apoptosis. Exposing human islets to high amounts of NO from chemical NO-donors causes DNA strand breaks and mitochondrial damage, suggesting that NO is deleterious to human beta-cells. Hence, we consider the gene encoding iNOS in beta-cells, NOS2, a candidate gene for type 1 diabetes in humans. In the present study we have tested three identified polymorphisms within the promoter sequence of the human NOS2 gene in a type 1 diabetic family material comprising 154 affected sib-pair families and 103 affected simplex families (1143 individuals in total). PCR-based amplification of the polymorphic loci were established. Linkage analysis was performed using the extended transmission disequilibrium testing (ETDT). A Bsal RFLP was found not to be polymorphic in 20 type 1 diabetic patients and 14 healthy control subjects and was not analysed further. In affected cases a nine allele CCTTT repeat and a bi-allelic TAAA repeat revealed allelewise P etdt of 0.52 and 0.60, respectively. ETDT applied to {(TAAA)n; (CCTTT)n} haplotypes demonstrated random transmission from heterozygous parents to affected offspring. In conclusion, the tested polymorphisms within the NOS2 gene promoter did not show evidence for linkage to type 1 diabetes in a Danish family material. Genes and Immunity (2000) 1, 362-366.
Introduction
Nitric oxide (NO) has been proposed as an effector molecule in cytokine mediated beta-cell destruction in type 1 diabetes. The effects of cytokines on beta-cell function were initially studied using isolated rodent islets of Langerhans exposed to cytokines in vitro, as reviewed in Mandrup-Poulsen. 1 Interleukin-1␤ (IL-1␤) inhibits betacell function and induces beta-cell cytotoxicity, as reviewed in Rabinovitch 2 and Eizirik and Pavlovic. 3 In rat beta-cells these effects have been suggested to be at least in part mediated by NO through the expression of inducible nitric oxide synthase (iNOS) mRNA and protein in beta-cells, leading to selective beta-cell destruction, as reviewed in Mandrup-Poulsen 1 and Eizirik and Pavlovic. 3 Likewise, inhibition of NO reduces the effects of cytokines in vitro 4 and reduces the incidence of diabetes in the BB rat. 5 Taken together, this demonstrates that iNOS induction and NO production play a central role in cytokine mediated rodent beta-cell destruction. Finally, different sensitivities towards the cytotoxic effects of IL-1␤ in two genetically different rat strains has been described in vivo as well as in vitro. 6, 7 In human islets of Langerhans a mixture of cytokines, eg, IL-1␤ + TNF␣ + IFN␥ induces expression of iNOS mRNA and NO production. [8] [9] [10] Furthermore, in human islets cytokine exposure inhibits glucose stimulated insulin release and decreases islet insulin content, although glucose oxidation is unaltered. 9 Cytokine exposure also decreases the DNA content, 9 induces DNA strand-breaks, and increases the number of apoptotic cells. 11 Finally, the NO-donor, Russian Black Salt, added in vitro to human islets has been shown to inhibit beta-cell function and induce DNA strand-breaks as well as beta-cell death. 12 On this basis, we consider the human NOS2 gene, which is the only gene responsible for NO production in betacells, to be a candidate gene for type 1 diabetes in man. We have used the extended transmission disequilibrium test (ETDT) as a test for linkage as: (i) the transmission disequilibrium test (TDT) was initially developed to identify linkage for minor susceptibility loci even when the loci did not appear in the genome scans, exemplified by the IDDM2 locus, 13 and (ii) the ETDT is a robust test for linkage in both multiplex and simplex families. 14, 15 The gene encoding for iNOS in man, NOS2 is located at chromosome 17q11.2-12. 16, 17 The human iNOS promoter region was originally cloned by Chartrain. 18 Promoter activity involves the 5Ј UTR spanning up to 16 kb upstream from the transcription start site, 19 with important cytokine responsive elements located −3.7 kb to −5.6 kb upstream of the transcription initiation start site. 20 In the human NOS2 promoter region three different polymorphisms have been identified in the −0.7 to −2.6 kb region: a single nucleotide polymorphism (G/C) causing a restriction enzyme site (Bsal) 21 and two microsatellites: a biallelic tetranucleotide repeat sequence (TAAA) n , 22 and a highly polymorphic (nine alleles) pentanucleotide repeat sequence (CCTTT) n . 23 The G/C has been associated with protection from all forms of severe malaria, 21 and the pentanucleotide repeat sequence have been functionally characterised in a promoter reporter assay. 24 The aim of the present paper was to test the three polymorphisms in the promoter region of the human NOS2 gene for linkage in a Danish Type 1 diabetes family material.
Results
The G/C in position −966 (GenBank accession number: X97821) was not polymorphic in a small panel of 20 type 1 diabetic patients and 14 healthy controls that all had the 'G' (wild-type) in position −966. This is in accordance with Kun et al, 21 who found no polymorphism in 100 German control subjects. Hence, this polymorphism was not further analysed.
The (TAAA) n repeat polymorphism in position −754 to −739 (GenBank accession number: X97821). Originally, this polymorphism was shown as a bi-allelic polymorphism in the sequence: CAAAAA-(TAAA) n -TAAAA, with three or four (TAAA)-repeats. We have identified a rare third allelic variant with two repeats, found only in one family (verified by cycle-sequencing; data not shown and not included in the calculations). The number of transmissions from heterozygous parents to affected and unaffected offspring are shown in Table 1 . Allele-wise P tdt are 0.60 for affected and 0.56 for unaffected offspring indicating no significant distorted transmission for any of the groups. Transmission to affected individuals has been stratified into affected below and above median age of onset (10.7 years), but no difference was observed; allelewise P tdt = 0.35 and 0.24, respectively.
Transmission data for the (CCTTT) n repeat sequence in position −2662 to −2608 (Gen-Bank accession number: X97821) are shown in Table 2 . In total, we identified nine different alleles, with number of repeats ranging from eight to 16. We did not find any distorted transmission for this polymorphism by ETDT to affected offspring (allele-wise P etdt = 0.52) or unaffected offspring (allelewise P etdt = 0.63). Stratification for age below and above (TAAA) n are located in position −751 to −736 (n = 4); GenBank accession number: X97821. Results are given as absolute transmissions and relatively to total transmissions, in parentheses.
Genes and Immunity median age of onset did not reveal any difference among affected by ETDT; P etdt = 0.39 and P etdt = 0.66, respectively. Haplotypes were constructed on basis of the (TAAA) n and the (CCTTT) n genotypes in all but three families. In total, 19 different haplotypes were constructed. In Table  3 , the 10 most common haplotypes are shown. Random transmission were observed for the haplotypes, allelewise ETDT: P etdt = 0.37 and 0.49 for affected and unaffected offspring, respectively. Neither did the ETDT reveal any distorted transmissions for haplotypes when data were stratified for each (TAAA) n repeat polymorphism nor for median age of onset (data not shown).
Discussion
In this study we have tested three different polymorphisms separately and constructed haplotypes in order to study the human NOS2 promoter sequence for linkage to type 1 diabetes mellitus. A single nucleotide polymorphism (G/C) located 0.9 kb upstream the NOS2 promoter region did not show any polymorphism in a total of 34 Danish individuals consistent with observations from a recent study. 21 This polymorphism is possibly restricted to populations subjected to selective pressure of Plasmodium falciparum and not to parasites in general, as only the wild-type allele was seen among 85 patients being serologically positive for Chagas' disease. 25 The repeat polymorphisms have previously been tested for association/linkage to other clinical conditions, where iNOS mediated NO production has been suggested to have a possible pathogenically role: in a study of hypertension, 26 as endothelial-derived relaxing factor has been identified as NO, and in a study of diabetic complications: diabetic retinopathy 24 and nephropathy 27 as these microangiopathies may be influenced by vascular functional disturbancies.
With respect to diabetic retinopathy, Warpeha et al 24 demonstrated an association of the (CCTTT) n repeat polymorphism as one allele was found to confer low risk of diabetic retinopathy in a mixed type 1 and 2 diabetic population. A functional significance was suggested, as the associated allele (14 repeats) was found to correlate with high activity in a promoter activity assay. 24 Recently, we have tested this polymorphism in Danish material comprising type 1 diabetic patients with diabetic nephropathy. As in retinopathy, an association of the 14-repeat allele was found, suggesting protection against diabetic nephropathy. 27 In the present study we have not been able to demonstrate linkage of this (CCTTT) n repeat sequence to type 1 diabetes.
In a recent Australian study testing both the (TAAA) n Only haplotypes representing more than ten transmissions are shown. In total 17 haplotypes could be constructed. and the (CCTTT) n repeat polymorphisms, neither association nor linkage to hypertension was observed for these polymorphisms. 26 Age-stratification of hypertensive patients showed association of the allele having four TAAA-repeat (named 'insertion', of the (TAAA) n polymorphism) among patients aged more than 60 years, when compared to younger hypertensive patients and to normotensive individuals. As no age-related differences could be demonstrated neither among normotensives tested for the (TAAA) n polymorphism nor for any hypertensives tested for the (CCTTT) n polymorphism, it was concluded that the initial observation suggests involvement of the tetranucleotide repeat to mortality in hypertension and not to hypertension as such. 26 In the present study, transmission analysis of the (TAAA) n repeat did not show linkage (P tdt = 0.60) to type 1 diabetes in the Danish population. Our data were age stratified on basis of the positive finding from the Australian hypertension study, although the Australian material was stratified for 'age of the individual' and not for 'age at onset of disease'. Secondly, as type 1 diabetes is considered a multifactorial disease, early onset could partly be due to a high genetic susceptibility load, or association/linkage of an allele that functionally increases diabetes risk. As different promoter activities have been suggested for the different alleles in the iNOS promoter, we stratified the iNOS promoter data below and above median age of onset, in order to divide the population in two equal sample sizes. No distorted transmissions were identified for either repeat polymorphism. Finally, we constructed haplotypes of the (TAAA) n and (CCTTT) n genotypes in order to increase the number of informative families/transmissions. No linkage could be demonstrated for haplotype data, further emphasising that no linkage to type 1 diabetes exist for the tested polymorphisms in the human iNOS promoter. Several possibilities exist why we have not been able to detect linkage to type 1 diabetes in our material. Obviously, it could be the case that no linkage exists for the tested polymorphisms. Power estimates for the diallelic (TAAA) n polymorphism to all affected (approximate 130 transmissions) reveal an approximate 45% risk of a type II error, in detecting a 12.5% deviation from the expected 50-50 transmission rate at a 5% significance level. This indicate that the (TAAA) n is not very informative in detecting linkage, due to a relative low heterozygosity of 0.21 in the present material. As the multiallelic (CCTTT) n and the haplotype data in the present material have a much higher heterozygosity of 0.79 and 0.83, respectively, the power is expected to be higher. 28 Secondly, as the human promoter has been reported to span up to 16 kb upstream from the transcription start site 19 other polymorphic regions may exist.
In conclusion, the present study did not demonstrate linkage for the human NOS2 gene promoter to type 1 diabetes in the Danish population. The possible existence of other polymorphisms in both the promoter region and the coding sequence of the human iNOS gene should be investigated and tested for potential involvement in the genetic predisposition to type 1 diabetes within different populations.
Materials and methods

Families
The study population comprised 257 Danish Caucasoid families, in total 1143 individuals. A total of 154 of the families were affected sib-pair families (totally 725 individuals), encountering 455 individuals (317 diabetics/138 unaffected) in the offspring generation. The remaining 103 families were simplex families (totally 418 individuals) including 114 unaffected offspring. All diabetic patients were diagnosed according to WHO criteria for type 1 diabetes and were diagnosed before the age of 30 years (median 10.7 years; range 0-30 years). 29, 30 The Danish National Ethics Committee approved the study.
DNA preparation and genotyping
DNA was prepared by standard procedures from leukocytes. 31 The PCR-based genotyping of three polymorphisms were performed as follows: (i) Bsal RFLP: Primers: F: 5Ј GGA ATG AGT GGA CAG GGG GAG CAA A 3Ј and R: 5Ј AAG ACT GGA GCG GAG TGG CAC GAT 3Ј. Amplification: 95°C for 10 min; 35 cycles each of 95°C for 30 sec/64°C for 30 sec/72°C for 30 sec; followed by 72°C for 10 min. PCR product digested with Bsal (2U/20 l PCR product) and run at agarose gel (2%) containing ethidium bromide for visualisation. (ii) (TAAA) n repeat: Primers: F: 5Ј TGC CAC TCC GCT CCA G 3Ј and P: 5ЈGGC CTC TGA GAT GTT GGT CTT 3Ј; and (CCTTT n -repeat): Primers: F: 5Ј CAC CCC TGG AAG CCT ACA ACT 3Ј and R: 5Ј GCC TGG GCA ACA TAG TGA GAT 3Ј. ␣ 33 P dCTP (stock: 370 MBq/ml) was incorporated in the product using the following amplification: 95°5 min, 35 cycles of 95°for 30 sec/62°for 30 sec/72°for 30 sec followed by 72°for 10 min. Samples were then electrophoresed on a 6% polyacrylamide gel. Gels were dried and exposed to X-ray films. All primers were designed from GenBank sequence accession number X97821. Haplotype construction of the two nucleotide repeat sequences was made in families where both genotypes of parents and offspring were informative; eg, father: {A-A, 1-2}, mother: {A-B, 3-4} and the offspring: {A-A, 2-3}. The haplotypes of the father being {A-1, A-2} and of the offspring {A-2, A-3} gives only one possibility for the mother: {A-3, B-4}. Heterozygosity of the markers was calculated on basis of the allele frequency in parents only.
Statistics
The nominal level of significance was set at P Ͻ 0.05 for the extended transmission disequilibrium test (ETDT version 1.1). 32 
